English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In light of current knowledge, the treatment with immunotherapy in advanced non-small cell lung cancer disease presents thebest results in patients with programmed death ligand 1 (PD-L1) + expression. We present two different clinical cases, both successful: the first refers to a 91-year-old male patient with 90% PD-L1 expression and high response rate to the treatment of immunotherapy with pembrolizumab at a dose of 200 mg every 3 weeks; in the second case, a 47-year-old female with PD-L1 negative expression and in whom immunotherapy was used as second line after progression under chemotherapy treatment and who also had a complete response with the use of atezolizumab at the dose of 1200 mg every 3 weeks.

Imunoterapia no Cancro do Pulmão de Não Pequenas Células Doença Avançada: A Propósito de Dois Casos Clínicos